Exercise of Share Options and Total Voting Rights

RNS Number : 1681S

Ergomed plc

06 July 2020

 

 PRESS RELEASE

Exercise of Share Options and Total Voting Rights

Guildford, UK - 6 July 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 100,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 9 July 2020.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission on 9 July 2020, the total number of ordinary shares with voting rights in issue will be 48,336,041. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

 

END

 

 

TVRRFMATMTBMBIM